Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: LIPOPROTEÍNAS, DOENÇAS CARDIOVASCULARES, FATORES DE RISCO, ARTERIOSCLEROSE
ABNT
BARKAS, Fotios et al. Global variation in lipoprotein(a) levels among patients with coronary heart disease insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies. Journal of the American College of Cardiology, v. 85, n. 21, p. 2028-2042, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/88283. Acesso em: 05 maio 2026.APA
Barkas, F., Brandts, J., Bacquer, D. D., Jennings, C., Backer, G. G. D., Kotseva, K., et al. (2025). Global variation in lipoprotein(a) levels among patients with coronary heart disease insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies. Journal of the American College of Cardiology, 85( 21), 2028-2042. doi:10.1016/j.jacc.2025.04.010NLM
Barkas F, Brandts J, Bacquer DD, Jennings C, Backer GGD, Kotseva K, Ryden L, Lip GYH, Santos Filho RD dos, Libby P. Global variation in lipoprotein(a) levels among patients with coronary heart disease insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies [Internet]. Journal of the American College of Cardiology. 2025 ; 85( 21): 2028-2042.[citado 2026 maio 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/88283Vancouver
Barkas F, Brandts J, Bacquer DD, Jennings C, Backer GGD, Kotseva K, Ryden L, Lip GYH, Santos Filho RD dos, Libby P. Global variation in lipoprotein(a) levels among patients with coronary heart disease insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies [Internet]. Journal of the American College of Cardiology. 2025 ; 85( 21): 2028-2042.[citado 2026 maio 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/88283
